For example, in the clinical trial KEYNOTE-021 (phase 2), carboplatin and pemetrexed in combination with pembrolizumab (PD-1 inhibitor) significantly improved response rate and progression-free survival (PFS) in patients with advanced non-squamous non-small cell lung cancer [92]. Here, PDCD1 is linked to non-small cell squamous lung carcinoma.